Real-world experience with alitretinoin in a community dermatology practice setting in patients with chronic hand dermatitis.

Abstract

BACKGROUND:

The treatment of moderate to severe chronic hand dermatitis (CHD) has been advanced with the introduction of alitretinoin (9-cis-retinoic acid). Although clinical trial data demonstrated the efficacy and safety of alitretinoin, real-world experience is lacking in a more generalized patient population.

OBJECTIVE:

Patients with CHD often, and unsuccessfully, attempt several therapeutic options before seeing a dermatologist. This chart review study aimed to examine the experience of using alitretinoin for CHD in a dermatology office setting.

METHODS:

A retrospective chart review of electronic medical records was conducted of all patients prescribed alitretinoin in a community dermatology practice.

RESULTS:

Alitretinoin was well tolerated in this patient population of 53 patients and showed a clinically significant reduction in disease symptoms.

CONCLUSION:

Alitretinoin was a safe and well-tolerated treatment with significant clinical improvement in our patient population. Few clinically significant laboratory abnormalities were identified, and only one patient discontinued therapy due to adverse events.

• Authors: Kaiya Ham, Priya Maini, Melinda J Gooderham
• Journal: Journal of cutaneous medicine and surgery (J Cutan Med Surg) Vol. 18 Issue 5 Pg. 332-6 (Oct 2014) ISSN: 1203-4754 [Print] United States
• PMID: 25186994 (Publication Type: Journal Article)

Chemical References

• Dermatologic Agents
• Alitretinoin
• Tretinoin

Topics

• Adult
• Aged
• Alitretinoin
• Chronic Disease
• Community Health Services
• Dermatologic Agents (adverse effects, therapeutic use)
• Dermatology
• Female
• Hand Dermatoses (drug therapy)
• Humans
• Male
• Middle Aged
• Retreatment
• Retrospective Studies
• Treatment Outcome
• Tretinoin (adverse effects, therapeutic use)